Axsome Therapeutics Inc.

6 hours ago · seekingalpha.com

Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript

9 hours ago · marketbeat.com

Axsome Therapeutics NASDAQ: AXSM reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer's disease agitation.

9 hours ago · zacks.com

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

11 hours ago · zacks.com

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.94 per share a year ago.

13 hours ago · globenewswire.com

Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI ® 3Q 2026 net product revenue of $48.2 million, representing 47% year-over-year growth SYMBRAVO ® 3Q 2026 net product sales of $3.9 million, representing 88% year-over-year growth SUMMIT Phase 3 trial of AXS-05 for smoking cessation initiated Company to host conference call today at 8:00 AM Eastern Time NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2026 and provided a general business update. “Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate.

7 days ago · zacks.com

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 days ago · fool.com

Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.

12 days ago · zacks.com

AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

21 days ago · fool.com

Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.

27 days ago · globenewswire.com

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2026 on Monday, November 2, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.